Back
Full-text
Journal article

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

  • Prins MH Department of Epidemiology and Technology Assessment, University of Maastricht, Maastricht, The Netherlands.
  • Lensing AWA Bayer AG, Leverkusen, Germany.
  • Prandoni P Department of Cardiothoracic and Vascular Sciences, Vascular Medicine Unit, University of Padua, Padua, Italy.
  • Wells PS Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Verhamme P Vascular Medicine and Hemostasis, University of Leuven, Leuven, Belgium.
  • Beyer-Westendorf J Department of Hematology, Medical Clinic I, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Bauersachs R Vascular Medicine, Klinikum Darmstadt, Darmstadt, Germany.
  • Bounameaux H Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
  • Brighton TA Department of Haematology, Prince of Wales Hospital, Sydney, Australia.
  • Cohen AT Department of Haematological Medicine, Guy's and St. Thomas' Hospitals, London, United Kingdom.
  • Davidson BL University of Washington School of Medicine, Seattle, WA.
  • Decousus H Centre d'Investigation Clinique 1408, Sainbiose U1059, Investigation Network On Venous Thromboembolism, Service de Médecine Vasculaire et Thérapeutique, Centre Hospitalo-Universitaire, Hôpital Nord, Saint Etienne, France.
  • Kakkar AK Thrombosis Research Institute and University College London, London, United Kingdom.
  • van Bellen B Hospital Beneficência Portuguesa, São Paulo, Brazil; and.
  • Pap AF Bayer AG, Leverkusen, Germany.
  • Homering M Bayer AG, Leverkusen, Germany.
  • Tamm M Bayer AG, Leverkusen, Germany.
  • Weitz JI Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, ON, Canada.
Show more…
  • 2018-04-11
Published in:
  • Blood advances. - 2018
Adult
Aged
Aspirin
Drug Administration Schedule
Factor Xa Inhibitors
Female
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors
Recurrence
Risk Assessment
Risk Factors
Rivaroxaban
Venous Thromboembolism
English The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In this prespecified analysis, we used data from 2 randomized trials, which compared once-daily rivaroxaban (20 mg or 10 mg) with aspirin (100 mg) or placebo for extended VTE treatment to estimate the risk of recurrence according to baseline risk factor profiles. Index VTE events were centrally classified as unprovoked, or provoked by major transient or persistent, or minor transient or persistent risk factors, and rates of recurrence at 1 year were calculated. A total of 2832 patients received rivaroxaban; 1131 received aspirin, and 590 received placebo. With unprovoked VTE, rates of recurrence in the 1173 patients given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2.0%, 5.9%, and 10.0%, respectively. There were no recurrences in patients with VTE provoked by major transient risk factors. With VTE provoked by minor persistent risk factors, recurrence rates in the 1184 patients given rivaroxaban, the 466 given aspirin, and the 248 given placebo were 2.4%, 4.5%, and 10.7%, respectively. For patients with minor transient risk factors, recurrence rates were 0.4% in the 268 patients given rivaroxaban, 4.2% in the 121 given aspirin, and 7.1% in the 56 given placebo. Recurrence rates in patients with VTE provoked by minor persistent or minor transient risk factors were not significantly lower than that with unprovoked VTE (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.56-1.16; and HR, 0.68; 95% CI, 0.32-1.30, respectively). Therefore, such patients may also benefit from extended anticoagulation therapy.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://sonar.ch/global/documents/252145
Statistics
Document views: 36 File downloads:
  • Full-text: 0